Unknown

Dataset Information

0

Characterization and treatment of gemcitabine- and cisplatin-resistant bladder cancer cells with a pan-RAS inhibitor.

ABSTRACT: Combination chemotherapy with gemcitabine and cisplatin (GC) is recommended as the primary treatment for advanced bladder cancer (BC). However, the benefits of this approach are limited owing to the acquisition of drug resistance. Here, we found that gemcitabine-resistant and cisplatin-resistant BCs do not exhibit cross-resistance, and that these BCs exhibit different mRNA patterns, as revealed using RNA sequence analysis. To overcome drug resistance, we used the newly developed pan-RAS inhibitor Compound 3144. Compound 3144 inhibited cell viability through suppression of RAS-dependent signaling in gemcitabine- and cisplatin-resistant BCs. RNA sequencing revealed that several genes and pathways, particularly those related to the cell cycle, were significantly downregulated in Compound 3144-treated BCs. These findings provide insights into potential therapeutic strategies for treating BC.

SUBMITTER: Yoshino H 

PROVIDER: S-EPMC10240337 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Combination chemotherapy with gemcitabine and cisplatin (GC) is recommended as the primary treatment for advanced bladder cancer (BC). However, the benefits of this approach are limited owing to the acquisition of drug resistance. Here, we found that gemcitabine-resistant and cisplatin-resistant BCs do not exhibit cross-resistance, and that these BCs exhibit different mRNA patterns, as revealed using RNA sequence analysis. To overcome drug resistance, we used the newly developed pan-RAS inhibito  ...[more]

Similar Datasets

Unknown Sulforaphane Inhibits Adhesion and Migration of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro.
| S-EPMC10934724 | biostudies-literature
Unknown A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer.
| S-EPMC4675549 | biostudies-literature
Unknown Successful treatment of metastatic bladder cancer by gemcitabine-cisplatin re-challenge after pembrolizumab.
| S-EPMC8560445 | biostudies-literature
Unknown Silencing of ECHDC1 inhibits growth of gemcitabine-resistant bladder cancer cells.
| S-EPMC5769416 | biostudies-literature
Unknown Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer.
| S-EPMC3964210 | biostudies-literature
Unknown Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters.
| S-EPMC8122772 | biostudies-literature
Unknown The Multi-Level Mechanism of Action of a Pan-Ras Inhibitor Explains its Antiproliferative Activity on Cetuximab-Resistant Cancer Cells.
| S-EPMC7925909 | biostudies-literature
Unknown Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells.
| S-EPMC4911881 | biostudies-literature
Unknown A Sos proteomimetic as a pan-Ras inhibitor.
| S-EPMC8106295 | biostudies-literature
Unknown Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report.
| S-EPMC9979306 | biostudies-literature